表紙
市場調査レポート

世界の血中循環核酸(CNA)による非侵襲的癌診断の市場

Circulating Nucleic Acids (CNAs) Based Non-Invasive Cancer Diagnostics: Global Market Report

発行 Veracity Health 商品コード 309759
出版日 ページ情報 英文 219 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
世界の血中循環核酸(CNA)による非侵襲的癌診断の市場 Circulating Nucleic Acids (CNAs) Based Non-Invasive Cancer Diagnostics: Global Market Report
出版日: 2014年07月28日 ページ情報: 英文 219 Pages
概要

当レポートでは、世界の血中循環核酸(CNA:Circulating Nucleic Acids)による非侵襲的癌診断の市場について調査し、CNAの種類と概要、CNAを利用した各種診断手法、癌の発症に関する統計、CNAを用いた癌診断の主な製品、CNAによる癌診断の収益分析および予測、地域・主要国の内訳、市場成長への影響因子の分析、競合環境と市場シェア、主要事業者のプロファイルなどをまとめています。

エグゼクティブサマリー

第1章 本書について

  • 本書の背景
  • 本書の目的・提供内容
  • 調査手法

第2章 血中循環核酸(CNA:Circulating Nucleic Acids)の背景

  • 血中循環核酸について
  • 血中循環核酸のカテゴリー
    • 血中循環無細胞DNA
    • 血中循環細胞外DNA
    • RNA
      • microRNA(miRNA)
      • miRNA模倣体・阻害剤
      • siRNA(Small Interfering RNA)
      • RNAi(RNA Interference)
  • 診断ツールとしての血中循環核酸
    • 癌バイオマーカーとしての血中循環DNA
    • 出生前診断での血中循環DNAの利用
    • 癌バイオマーカーとしての血中循環RNA
    • 妊娠中の血中循環RNA
  • 血中循環核酸の検出に用いられる手法

第3章 癌:疾患の発症率・有病率の統計分析

  • イントロダクション
  • 世界の統計サマリー:発症率推計・死亡率・5年有病率
    • 癌の種類別
    • 男性・癌の種類別
    • 女性・癌の種類別
  • WHOによる南北アメリカの統計サマリー:発症率推計・死亡率・5年有病率:癌の種類別
  • WHOによる欧州地域の統計サマリー:発症率推計・死亡率・5年有病率:癌の種類別
  • WHOによるアフリカの統計サマリー:発症率推計・死亡率・5年有病率:癌の種類別
  • WHOによる地中海東部の統計サマリー:発症率推計・死亡率・5年有病率:癌の種類別
  • WHOによる東南アジアの統計サマリー:発症率推計・死亡率・5年有病率:癌の種類別
  • WHOによる太平洋西部の統計サマリー:発症率推計・死亡率・5年有病率:癌の種類別

第4章 CNAによる癌診断市場:収益分析

  • イントロダクション
  • 市場力学
    • 市場成長推進因子
    • 市場成長阻害因子
  • 主なCNAによる癌診断製品
  • 市場収益分析
    • 世界市場の収益分析
    • 世界市場の収益分析:地域別
    • 市場収益分析:主要国別

第5章 CNAによる癌診断市場:市場シェア分析

  • 市場シェア分析
    • 世界市場シェア分析
    • 市場シェア分析:地域別
    • 市場シェア分析:主要国別

第6章 企業プロファイル

  • Abbott Laboratories (Abbott Molecular)
  • Affymetrix Inc
  • Autogenomics
  • Becton Dickinson and Company (BD)
  • Beckmann Coulter, Inc (Danaher Corporation)
  • bioMerieux
  • Cancer Genetics, Inc
  • Cepheid
  • Dako (Agilent)
  • Epigenomics
  • Hologic Gen-Probe
  • Illumina
  • Ipsogen (Qiagen)
  • Luminex
  • MolecularMD
  • Myriad Genetics Laboratories
  • Novartis Diagnostics
  • Ortho-Clinical Diagnostics (The Carlyle Group)
  • Oxford Gene Technology (OGT)
  • Qiagen N.V
  • Roche
  • Siemens
  • Sysmex Corporation
  • Thermo Fisher Scientific
  • Ventana (Roche)

用語

目次

The aim of this report was to review recent advances in use of circulating cell-free miRNA, DNA and mRNA as novel biomarkers which can be used for the detection and diagnosis of cancer, and the impact on making the ongoing research closer to clinical application. The report will also provide a market analysis of the market value, growth rates, market development as well as examining the dynamics and factors influencing the growth and development of this market. This report also looks at the challenges and potential threats facing the industry players, and the factors influencing the market shares of both the major market suppliers and smaller indigenous manufacturers in local markets.

The data collection and forecasting methods used in the preparation of this report are broadly divided into three methods. These are primary data and information gathering, secondary data and information gathering and market share analysis and market forecast prediction. Information and data including estimates on market values, growth rates and market share data were gathered from the methods described and were incorporated into proprietary computer forecasting and market share analysis models. The forecast model was used to derive market estimates for future years. It incorporates a rate factor, which helps determine the speed with which the market develops, which is similar to that observed for markets for other medical products and is adjusted to match historic data for the market under analysis.

Table of Contents

ES.1. Introduction to the Circulating Nucleic Acid Market Report

ES.2. Background to Circulating Nucleic Acids

ES.3. Cancer: A Statistical Analysis of the Disease Incidence and Prevalence

ES.4. CNA Based Cancer Diagnostics Market: Revenue Analysis

  • Exhibit E.S. 1: Global Market Revenue Forecast - CNA Based Non-invasive Cancer Diagnostic Products (2010 - 2020)

ES.5. CNA Based Cancer Diagnostics Market: Market Share Analysis

  • Exhibit E.S. 2: Global Market Share Analysis - CNA Based Non-invasive Cancer Diagnostic Products (2013)
  • Exhibit E.S. 3: Global Market Share Analysis - CNA Based Non-invasive Cancer Diagnostic Products (2013)

ES.6. Company Profiles

  • 1.1. Report Background
  • 1.2. Report Objectives and Deliverables
  • 1.3. Methodology
  • 2.1. Introduction to Circulating Nucleic Acids (CNAs)
  • Exhibit 2.1: Major Developments in Understanding Nucleic Acids and their Cellular Roles
  • Exhibit 2.2: Circulating DNA Concentrations in Blood of Healthy Donors and Selected Cancer Patients
  • 2.2. Categories of Circulating Nucleic Acids
    • 2.2.1. Circulating Cell-Free DNA
    • 2.2.2. Circulating Extracellular DNA
    • 2.2.3. RNA
      • 2.2.3.1. microRNAs (miRNAs)
      • 2.2.3.2. miRNA Mimics and Inhibitors
      • 2.2.3.3. Small Interfering RNA (siRNA)
      • 2.2.3.4. RNA Interference (RNAi)
  • 2.3. Circulating Nucleic Acids as a Diagnostic Tool
    • 2.3.1. Circulating DNA as a Biomarker of Cancer
    • 2.3.2. Use of Circulating DNA for Prenatal Diagnosis
    • 2.3.3. Circulating RNA as a Biomarker of Cancer
  • Exhibit 2.3: Circulating Tumour-Associated miRNAs as potential biomarkers in Lung Cancer
  • Exhibit 2.4: Circulating Tumour-Associated miRNAs as potential biomarkers in Breast Cancer
  • Exhibit 2.5: Circulating Tumour-Associated miRNAs as potential biomarkers in Prostate Cancer
  • Exhibit 2.6: Circulating Tumour-Associated miRNAs as potential biomarkers in Ovarian Cancer
  • Exhibit 2.7: Circulating Tumour-Associated miRNAs as potential biomarkers in Bladder Cancer
  • Exhibit 2.8: Circulating Tumour-Associated miRNAs as potential biomarkers in Pancreatic Cancer
  • Exhibit 2.9: Circulating Tumour-Associated miRNAs as potential biomarkers in Gastric Cancer
  • Exhibit 2.10: Circulating Tumour-Associated miRNAs as potential biomarkers in Liver Cancer
  • Exhibit 2.11: Circulating Tumour-Associated miRNAs as potential biomarkers in Colo-Rectal Cancer
  • Exhibit 2.12: Circulating Tumour-Associated miRNAs as potential biomarkers in Oral Cancer
  • Exhibit 2.13: Circulating Tumour-Associated miRNAs as potential biomarkers in Esophageal Cancer
  • 2.3.4. Circulating RNA in Pregnancy
  • 2.4. Methods Used for the Detection of Circulating Nucleic Acids
    • Exhibit 2.4: Top molecular CNA Characterisation Techniques
    • Exhibit 2.5: Top molecular CNA Characterisation Techniques
  • 3.1. Introduction
  • 3.2. Global Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence
    • Exhibit 3.1: Summary Statistics (Global): Estimated Incidence, Mortality and 5-year Prevalence (2012)
    • 3.2.1. Global Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence (Both Sexes) by Cancer Type
      • Exhibit 3.2: Summary Statistics (Global): Estimated Incidence, Mortality and 5-year Prevalence (Both Sexes) by Cancer Type (2012)
    • 3.2.2. Global Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence (Male) by Cancer
      • Exhibit 3.3: Summary Statistics (Global): Estimated Incidence, Mortality and 5-year Prevalence (By Male) by Cancer Type (2012)
    • 3.2.3. Global Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence by Cancer Type
    • Exhibit 3.4: Summary Statistics: Estimated Incidence, Mortality and 5-year Prevalence (By Female) by Cancer Type (2012)
  • 3.3. WHO Americas Region Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence by Cancer Type
    • Exhibit 3.5: WHO Americas Region Summary Statistics (Global): Estimated Incidence, Mortality and 5-year Prevalence (Both Sexes) by Cancer Type (2012)
  • 3.4. WHO European Region Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence by Cancer Type
    • Exhibit 3.6: WHO European Region Summary Statistics (Global): Estimated Incidence, Mortality and 5-year Prevalence (Both Sexes) by Cancer Type (2012)
  • 3.5. WHO African Region Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence by Cancer Type
    • Exhibit 3.7: WHO African Region Summary Statistics (Global): Estimated Incidence, Mortality and 5-year Prevalence (Both Sexes) by Cancer Type (2012)
  • 3.6. WHO Eastern Mediterranean Region Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence by Cancer Type
    • Exhibit 3.8: WHO Eastern Mediterranean Eastern Mediterranean Region Summary Statistics (Global): Estimated Incidence, Mortality and 5-year Prevalence (Both Sexes) by Cancer Type (2012)
  • 3.7. WHO South East Asia Region Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence by Cancer Type
    • Exhibit 3.9: WHO South East Asia Region Summary Statistics (Global): Estimated Incidence, Mortality and 5-year Prevalence (Both Sexes) by Cancer Type (2012)
  • 3.8. WHO Western Pacific Region Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence by Cancer Type
    • Exhibit 3.10: WHO Western Pacific Region Summary Statistics (Global): Estimated Incidence, Mortality and 5-year Prevalence (Both Sexes) by Cancer Type (2012)
  • 4.1. Introduction
  • 4.2. Market Dynamics
    • 4.2.1. Market Drivers
      • 4.2.1.1. Evolving Paradigm Shift in Disease Diagnostics
      • 4.2.1.2. Significant Advantages over Conventional Screening and Diagnostic Methods
      • 4.2.1.3. Research and Development of New and Innovative Enabling Technologies
    • 4.2.2. Market Restraints
      • 4.2.2.1. Securing Appropriate Reimbursement Schedules
      • 4.2.2.2. Social, Ethical and Regulatory Issue for Implementation of Circulating Nucleic Acid Diagnostic Technologies
      • 4.2.2.3. Technical Issues: Sample Collection, Handling, Extraction, Transportation and Storage etc Cause Concerns over Practical Use of Circulating Nucleic Acids
  • 4.3. Selected CNA Cancer Diagnostic Products
    • Exhibit 4.1: Featured CNA Cancer Diagnostic Products
  • 4.4. Market Revenue Analysis
    • 4.4.1. Global Market Revenue Analysis
      • 4.4.1.1. Total Market Revenue Analysis
        • Exhibit 4.2: Global Market Revenue Forecast (2010 - 2020)
    • 4.1.1. Market Revenue Analysis by Geographic Region
      • Exhibit 4.3: Global Market Revenue Forecast (2009 - 2019)
      • Exhibit 4.4: Market Revenue Forecast by Geographic Countries - (2010 - 2020)
      • Exhibit 4.5: Percentage Share of Global Market Revenue Forecast by Geographic Region - CNA Based Cancer Diagnostics (2010 - 2020)
      • Exhibit 4.6: Percentage Share of Global Market Revenue Forecast by Geographic Region - CNA Based Cancer Diagnostics (2010 - 2020)
    • 4.1.2. Market Revenue Analysis by Selected Country
      • Exhibit 4.6: Market Revenue Forecast by Selected Countries - (2010 - 2020)
      • Exhibit 4.7: Market Revenue Forecast by Selected Countries - (2010 - 2020)
  • 5.1. Market Share Analysis
    • 5.1.1. Global Market Share Analysis
      • Exhibit 5.1: Global Market Share Analysis - CNA Based Non-invasive Cancer Diagnostic Products (2013)
      • Exhibit 5.2: Global Market Share Analysis - CNA Based Non-invasive Cancer Diagnostic Products (2013)
    • 5.5.2. Market Share Analysis by Geographic Region
      • Exhibit 5.3: Market Share Analysis by Geographic Region - Non-invasive Cancer Diagnostic (2013)
    • 5.5.3. Market Share Analysis by Selected Country
      • Exhibit 5.4: Market Share Analysis by Selected Country - Non-invasive Prenatal Diagnostics (2013)
  • 6.1. Abbott Laboratories (Abbott Molecular)
  • 6.2. Affymetrix Inc
  • 6.3. Autogenomics
  • 6.4. Becton Dickinson and Company (BD)
  • 6.5. Beckmann Coulter, Inc (Danaher Corporation)
  • 6.6. bioMérieux
  • 6.7. Cancer Genetics, Inc
  • 6.8. Cepheid
  • 6.9. Dako (Agilent)
  • 6.10. Epigenomics
  • 6.11. Hologic Gen-Probe
  • 6.12. Illumina
  • 6.13. Ipsogen (Qiagen)
  • 6.14. Luminex
  • 6.15. MolecularMD
  • 6.16. Myriad Genetics Laboratories
  • 6.17. Novartis Diagnostics
  • 6.18. Ortho-Clinical Diagnostics (The Carlyle Group)
  • 6.19. Oxford Gene Technology (OGT)
  • 6.20. Qiagen N.V
  • 6.21. Roche
  • 6.22. Siemens
  • 6.23. Sysmex Corporation
  • 6.24. Thermo Fisher Scientific
  • 6.25. Ventana (Roche)
  • Glossary of Acronyms
Back to Top